Recent Research Analysts’ Ratings Changes for PetMed Express (PETS)

Several brokerages have updated their recommendations and price targets on shares of PetMed Express (NASDAQ: PETS) in the last few weeks:

• 10/14/2026 – PetMed Express was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 9/29/2026 – PetMed Express was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 9/25/2026 – PetMed Express had its price target lowered by Morgan Stanley from $2.15 to $1.40. They now have an “underweight” rating on the stock.
• 9/25/2026 – PetMed Express was downgraded by Zacks Research from “hold” to “strong sell”.
• 9/9/2026 – PetMed Express was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 8/24/2026 – PetMed Express was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.

PetMed Express, Inc is an online pet pharmacy and specialty retailer that markets pet medications, food, and healthcare products directly to consumers. The company operates under the 1-800-PetMeds brand and focuses primarily on products for dogs and cats.

Its product offerings include prescription and nonprescription medications, flea and tick treatments, heartworm preventives, supplements, and other veterinary health products. PetMed Express also sells pet food, treats, supplies, and select general wellness products through its digital platforms and customer service channels.

Founded in 1996, the company serves pet owners throughout the United States.